In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immerge BioTherapeutics Inc.

Latest From Immerge BioTherapeutics Inc.

Leading a Biotech Through Crisis

Given the cyclical nature of the biotech industry, companies--both public and private--are forced to weather financing storms every few years. During lean times, one strategy is to cut operations to create the basis for a financing event and stave off the inevitable cash cliff. But a company focusing all its efforts on one, or at most a few, projects has very little to fall back on should its lead opportunity fail. And the equity markets may not come back in time. BioTransplant's CEO-Donald Hawthorne, brought in to save the company, understood from the beginning that companies with just a few months of cash left tend to fail. His challenge: to avoid failure, while at the same time maximizing the chance that in the event of bankruptcy, at least some of the assets of the company could create additional value.
BioPharmaceutical Business Strategies

Selected Start-Ups (03/01)

In Vivo summarizes the technology of several recently founded companies: Germany's Curacyte AG was formed to commercialize platforms in oncology, immunology and hematological disorders; Eliance Biotechnology Inc. has licensed a vaccine discovery platform that identifies the optimal antigens for vaccine production; Immerge Biotherapeutics will focus on the development of swine-based cells, tissues and organs for transplantation into humans; MedLynx Corp. aims to reduce hospital operating costs and reduce medical errors with its wireless, handheld medical information management system; Perlegen Sciences Inc. will read genomes from 50 individuals to discover and analyze patterns of genetic variation; Protiva Biotherapeutic Inc's gene delivery technology protects plasmid DNA from degradation as the particles are delivered through the bloodstream to their destination
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Immerge BioTherapeutics Inc.
  • Senior Management
  • Julia Greenstein, PhD, Pres. & CEO
    Henk Schuurman, PhD, VP, Research
  • Contact Info
  • Immerge BioTherapeutics Inc.
    Phone: (617) 241-5565
    Charlestown Navy Yd.
    Charlestown, MA 02129
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register